First held in 1985 as a roundtable of 20 participants, the NF Conference is now the most important scholarly gathering of the NF research and clinical communities. For the first time in nearly 40 years, the NF Conference will be held outside of the United States. From November 2 thru November 6, 2018 in Paris, France, we are co-hosts of the Joint Global Neurofibromoatosis Conference, a global event attracting more than 800 participants worldwide across a wide range of scientific disciplines, from research and clinical backgrounds, all focused on improving outcomes for patients with neurofibromatosis type 1 (NF1), neurofibromatosis type 2 (NF2) and schwannomatosis. The NF Conference continues to be a critical forum for consensus building and advancing basic, translational, and clinical research in NF and related fields, while fostering collaborations within and beyond the NF community.
These video Q&As will touch on some of the topics that will be addressed and who should attend this meeting.
A WELCOME MESSAGE TO THE PARIS NF CONFERENCE FROM PROFESSOR PIERRE WOLKENSTEIN!
QUESTION: WHY DID CTF AND THE EUROPEAN NF GROUP JOIN FORCES THIS YEAR FOR ONE GLOBAL MEETING?
ANSWER:
Maurizio Clementi, Full Professor of Medical Genetics, Director of Clinical Genetics Unit, University of Padova, Padova, Italy
QUESTION: DOES NEUROFIBROMATOSIS AFFECT ALL NATIONALITIES?
ANSWER:
Susan Huson, Consultant Clinical Geneticist, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE INTERESTED IN ANIMAL MODELS?
ANSWER:
Piotr Topilko, Senior Research Assistant – INSERM, Paris, France
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE INTERESTED IN NEUROFIBROMATOSIS TYPE 2?
ANSWER:
Gareth Evans, Cancer Lead and Consultant in Clinical Genetics Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
QUESTION: WHY ATTEND THE PARIS MEETING IF YOU STUDY MALIGNANT NERVE SHEATH TUMORS?
ANSWER:
Rosalie Ferner, MD, FRCP Consultant Neurologist, Centre Department of Neurology Guy’s Hospital Great Maze Pond London, London, UK
QUESTION: WILL WE HAVE NEWS ON EPIGENETICS DURING THE PARIS MEETING?
ANSWER:
Eric Pasmant, Department of Molecular Genetics, Cochin Hospital, Paris Descartes University, Paris, France
QUESTION: WILL THERE BE SOME NEWS ON EPIDEMIOLOGY OF NEUROFIBROMATOSIS IN THE PARIS MEETING?
ANSWER:
Juha Peltonen, Clinical Expert, Investigator of research project- Institute of Biomedicine, University of Turku, Turku, Finland
QUESTION: WILL THERE BE SOME NEWS ON NF1 GENOTYPING AT THE PARIS MEETING?
ANSWER:
Meena Upadhyayah, Professor of Medical Genetics, Cardiff University, Cardiff, UK
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE A NEUROLOGIST?
ANSWER:
Thijs Van der Vaart, Resident in Neurology, Erasmus MC, Rotterdam, The Netherlands
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE A GENETICIST?
ANSWER:
Benoît Funalot, PUPH Génétique, Créteil, France
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE A CLINICAL GENETICIST?
ANSWER:
Eric Legius, MD, PHD, Professor Human Genetics, Kuleven, Belgium
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE A MOLECULAR GENETICIST?
ANSWER:
Conxi Lazaro, Head of the Molecular Diagnostic Unit Hereditary Cancer Program Laboratori de Recerca Translacional, Institut Catalan of Oncology, Barcelona, Spain
QUESTION: WHY ATTEND THE PARIS MEETING WHEN YOU ARE A PATHOLOGIST?
ANSWER:
Nicolas Ortonne, PUPH Pathologie, Créteil, France
For more information and to register, visit ctf.org/nfconference.
